“…Considering the observation of both reduced toxicities and inferior survival in the Hispanic cohort, the possibility of suboptimal drug exposure in these patients likely deserves further inquiry. Thus, while differences in both host and leukemia biology are prognostically important, future studies will also focus on host pharmacogenomics, detailed analyses of nutrition status and obesity trends, interpatient differences in biomarkers of drug exposure, frequency of drug interruptions for toxicity, and oral chemotherapy adherence.…”